CTDSPL

Across TCGA pan-cancer cohorts, CTDSPL Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CTDSPL data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher CTDSPL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CTDSPL expression acts as an unfavorable survival marker.

MESO, BLCA, and ACC are the cancer types where CTDSPL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.077	0.580	<.001	42	view →
BLCA	OS	Median	All	0.132	0.720	<.001	42	view →
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
KICH	OS	Median	II,III,IV	0.161	0.827	.004	13	view →
LIHC	OS	Median	All	0.059	0.783	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CTDSPL–MESO (OS)

Open the MESO breakdown →